Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Tipranavir/Ritonavir on Norethindrone-Ethinyl Estradiol PK
NCT02245438Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- May 2002
- Primary completion
- Jun 2002
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of tipranavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under plasma concentration time curve, Maximum plasma concentration and 1 more. Started May 2002; status: terminated.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02245438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02245438.